Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- Mundipharma Obtains Exclusive Rights in Japan from South Korean Firm for Osteoarthritis Cell Therapy
November 22, 2018
- Takeda Voluntary Recalls 7 Narcotic Injectable Products after Confirming Coloring
November 22, 2018
- Takeda Gets European OK for Shire Deal with Strings Attached
November 21, 2018
- Pfizer’s ALK Inhibitor Lorbrena, Shire’s HAE Drug Now Available in Japan
November 21, 2018
- AbbVie Seeks Japan Approval for BCL-2 Inhibitor Venetoclax in CLL
November 21, 2018
- Takeda to Issue US$5.5 Billion in Bonds for Shire Acquisition
November 21, 2018
- Mitsubishi Tanabe Cuts FY2020 Targets in 5-Year Biz Plan on Flagging Royalty, Development Delay
November 21, 2018
- Sawai to Attach More Weight to Profits, Received Several Approaches for Possible Tie-Up: Chief
November 20, 2018
- Amgen Astellas’ Migraine Drug Hits Primary Endpoint in Japan PII
November 20, 2018
- 3 Japan Generic Majors Log 6% Growth in Combined April-September Sales despite Price Revision
November 20, 2018
- Fuji Pharma to Bolster Biosimilar Business as New Core
November 20, 2018
- High Court Upholds Not-Guilty Ruling for Novartis, Ex-Employee in Diovan Case
November 20, 2018
- Toray to Develop Small Molecule Cancer Drug Licensed from US Bioventure
November 20, 2018
- Chugai Sues Alexion in US over Soliris Successor ALXN1210
November 19, 2018
- 4 Major Wholesalers See 46.1% Increase in 1st Half Operating Profit due to Reductions in Yakkasa and SGA Costs
November 19, 2018
- Takeda to Procure €7.5 Billion in Bonds for Shire Acquisition
November 19, 2018
- AstraZeneca Japan Set to Roll Out 4 New Treatments Every Year through 2021: Chief
November 16, 2018
- Talion AG Contributes to Nipro’s Strong Generic Biz Growth
November 16, 2018
- Novo to Develop New Dosages for Ozempic, 14-Day Prescription Limit Weighs
November 16, 2018
- NapaJen Pharma Initiates PI Trial of Oligonucleotide Therapeutic in Australia
November 16, 2018
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…